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Abstract 
 
Introduction 
Dengue is one of the most important emerging infections with 50% of the world’s 
population living in dengue endemic countries. The clinical spectrum of disease can 
range from asymptomatic to a severe haemorrhagic illness. Those with secondary 
infection with a second serotype are most at risk of severe disease. This has lead to the 
theory that a primed immune response ineffectively clears a secondary infection and 
enhances infection. Teasing out immunology to dengue has become important in aiding 
effective and safe vaccine design. In this project, I investigated the antibody response of 
a case of acute severe primary dengue. 
Methods 
Activated B cells were isolated from a patient with acute severe dengue virus. 
Recombinant monoclonal antibodies (mAbs) were produced and investigated. The 
mAbs were assessed for: their ability to recognise dengue; epitopes to which they bind; 
which amino acids of the structural proteins they bind to. 
Results 
88 IgH-Igλ and 44 IgH-Igκ recombinant IgG antibodies were produced. 44 mAbs were 
investigated further. Seven of the mAbs showed reactivity to dengue, 3 reacting to 
dengue 1 alone, 3 had cross reactivity to all four serotypes and JE. Western blot revealed 
that no antibodies bound to prM or E. A viral like protein (VLP) library was created for 
further assessment of epitope binding.  
Discussion 
IgG was produced to dengue despite the early time point. Interestingly 43% (n=3) of 
antibodies were specific to the infecting dengue serotype, but a further 43% were 
reactive to all four dengue serotypes. The epitopes for these mAbs were not 
demonstrated. This may be due to changes to the E and prM proteins during the 
Western blot that mAbs recognise other epitopes or else the mAbs react to tertiary 
 3 
structure epitopes. Use of the VLP library to identify the amino acid residues necessary 
for binding would help in understanding the epitopes. 
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Introduction 
 
Historical Perspective 
Dengue is a flavivirus transmitted by Aedes mosquitoes and is endemic throughout 
tropical and sub-tropical regions of the world. The first record of dengue is from a 
Chinese medical encyclopaedia originally published in the Qin Dynasty (265-420AD). It 
was referred to as ‘water poison’ and was associated with flying insects [10]. Historical 
epidemics resembling dengue have been documented in the 17th century in the West 
Indies and Central America. [11] [12] By the 1800s, the disease was widespread 
throughout urban tropical coastal cities due to the shipping trade [11]. World War II 
resulted in rapid global expansion in dengue transmission due to population dispersal, 
troop movements and social disarray. [13] Later in South America, the yellow fever 
disease control campaign, which saw widespread DDT spraying, resulted in near 
elimination of dengue. However, once the campaign was discontinued in the 1970s, 
dengue saw a resurgence and by 1995, had returned to pre-campaign levels.  
 
Dengue virus and transmission 
Dengue is an arbovirus and a member of the flavivirus genus. Other closely related 
members of the flavivirus family include Japanese encephalitis (JEV), yellow fever virus 
(YFV), West Nile virus (WNV) and tick borne encephalitis virus (TBEV).  
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Humans are the main amplifying host for dengue virus, although non-human primates 
may rarely be infected. The virus is transmitted from viraemic humans to female Aedes 
mosquitoes during a blood meal. The principal mosquito is  A. aegypti, however A. 
albopictus may also transmit dengue. These are day biting mosqitoes that breed in both 
clean and stagnant water and are readily adapted to urban environments. They are able 
to breed in small pools of water in domestic settings, such as house plants, guttering or 
open water butts. Female mosquitoes also preferentially feed and rest indoors further 
improving their disease transmission efficiency. [14] 
 
Once the mosquito is infected from a blood meal, the virus infects the midgut of the 
mosquito, then spreads systemically over 8-12 days, at which point it infects the 
salivary glands (and remains there for the duration of the mosquitoes’ life) and becomes 
infectious to humans. [1] 
 
Epidemiology and Public Health Significance 
There has been a precipitous increase in dengue incidence over the last 50 years and 
dengue is now one of the most important emerging global diseases [1] [Fig. 1].  It has 
expanded geographically and approximately 50% of the world’s population are living in 
dengue endemic countries [11]. There are approximately 390 million dengue infections 
worldwide annually, with 96 million that are clinically manifest [2] [Fig. 2].  
Approximately 75% of the world’s dengue burden is in South Eastern Asia and Western 
Pacific regions. [1] However, 2012 saw large outbreaks throughout South America. A 
number of small outbreaks over recent years have occurred in sub-tropical regions, 
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namely Madeira 2012, Florida 2013 and Tokyo 2014. [15] [16] [17] [18]  Concern over 
global warming has suggested that Aedes mosquitoes may be able to survive in new 
regions raising concerns that spread to sub-tropical areas may be permanent. [19]  
 
Fig. 1. Average annual number of dengue fever and dengue haemorrhagic fever cases as 
reported to the WHO 1955-2007. Showing the precipitous increase in cases [1]. 
 
 
 
 
 
 
 15 
Fig. 2. Global evidence of risk and burden of dengue disease in 2010 [2]. A. national and 
subnational consensus on data avaiable for dengue infections. B. Assessment of probability of 
dengue occurrence at 5km x 5km spatial resolution. C. cartogram of annual number of infections 
for all ages as a proportion of national or subnational geographic data. 
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Dengue virus, its transmission and cell cycle 
Dengue virus (DENV) is a small icosahedral enveloped virus with a single stranded (ss) 
positive sense RNA genome.  There are four serotypes 1-4, each serotype being 
composed of 3-6 genotypes. [20] The serotypes possess 67-73% identity at the 
nucelotide level, and 69-78% identity at the amino acid level. Phylogenetic studies 
suggest that dengue may have emerged from a sylvatic virus. Serotype diversity may 
have occurred as populations became isolated and the viruses genetically diversified.  
 
The dengue virus genome is approximately 10kB in length and consists of a small 5’ 
untranslated region (UTR) (~100bp), a single open reading frame (ORF) and a 3’ UTR of 
400bp. The ORF encodes  3 structural genes (capsid (C), pre-membrane (prM) and  
envelope (E)) and 7 non-structural genes (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) 
[Fig. 3.]. The envelope protein contains three regions DI- DIII. Functions of the viral 
proteins are detailed in fig. 3. The ORF is translated as a single polyprotein of 3387-
3392 amino acids that undergoes co- and post-translational modification by viral and 
host proteinases [22, 23][22, 23][21, 22](Urcuqui-Inchima, Patino et al. 2010)(Urcuqui-
Inchima, Patino et al. 2010)(Urcuqui-Inchima, Patino et al. 2010)(Urcuqui-Inchima, 
Patino et al. 2010)(Urcuqui-Inchima, Patino et al. 2010)(Urcuqui-Inchima, Patino et al. 
2010)(Urcuqui-Inchima, Patino et al. 2010)(Urcuqui-Inchima, Patino et al. 
2010)(Urcuqui-Inchima, Patino et al. 2010) . 
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Fig. 3 Phylogenetic tree of all 4 strains of DENV derived from the complete open 
reading frame from GenBank. [21] 
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Fig. 4. Schematic representation of dengue genome with proposed functions of the 
proteins 
Structural                                                                    Non-structural 
 
 
C Capsid  
 Signal peptides for translocation to ER and nuclear localisation 
prM E protein chaperone during exocytosis 
 Prevention of premature fusion 
E Receptor binding and fusion activity 
 Major target of neutralising antibodies 
NS1 May define pathogenesis 
 Possibly interacts with NS4A 
NS2A Involved in interferon signalling (with NS4A and NS4B) 
NS2B Cofactor of NS3 
NS3 Protease  
 Helicase 
NS4A Probably involved in RNA replication 
 Induced membrane rearrangements 
NS4B Blocks IFN-induced signal transduction cascade 
 Interacts with NS3 and dissociates it from ssRNA 
NS5 Methylation of viral RNA cap 
 Possesses nuclear export signal 
Reduces expression of STAT2 
C  prM       E            NS1          NS2A  NS2B                  NS3              NS4A     NS4B                NS5 
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The structure of the mature dengue virus particle propogated at 30c has been shown to 
be an icoashedral structure made up of 90 E protein dimers in a herringbone pattern. 
This creates a smooth surface. Each E protein is 495 amino acids long and is made up of 
a C terminal transmembrane region and an ectodomain of three regions, DI, DII, DIII. 
DIII has an immunoglobulin like structure and protrudes from the surface, where as DII 
is key in membrane fusion [3] [Fig. 4] 
 
Fig. 5. Structure of the soluble E dimer and the mature virus particle [3]. A. shows the 
structure of the E protein with Domain I as red, domain II yellow and domain II as blue. B. 
Shows the conformation of the E protein in the mature virus particle. C. shows the packing of 
the e protein on the surface of mature virus particle.  
 
 
 
The prM protein consists of an N terminal pr region, a furin cleavage site followed by 
the M protein. The M protein is made up of α helix stem and two transmembrane 
regions.  
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The immature viral particle is larger at 600A, as compared to the mature size of 500A,  
remains an icosahedral shape, but is spiky. There are 60 spikes, which are made up of 
quasi-trimers of 2 E proteins and an uncleaved precurser-Membrane (prM) protein 
[23]. Recent studies have found that mature viral particles propogated at human 
physiological temperature, 37c (and indeed temperatures higher than 33c) are 
‘bumpy’ with the E protein rotated 60 [24] [Fig. 5]. 
 
Fig. 6 Structure of the ‘bumpy’ virus by cryo-EM [25]. The structure of the high temperature 
bumpy virus. A. cryo-EM of the bumpy virus coloured by the radial distance from the centre of 
the virus. B. E dimers fitted into the elctron density map. C. The structure of the bumpy virus 
particles, DI red, DI yellow, DII blue. Compare with figure 4 where the particle is fully mature. 
 
 
Dengue virus in the cell 
In humans, the initial target cells are thought to be immature dentritic cells [26]. Other 
cells thought to be infected are monocytes, macrophages, and possibly Kupffer cells, 
hepatocytes and lymphocytes [27, 28]. It is thought that numerous negatively charged 
glycoaminoglycans such as heparan sulphate form low affinity attachments with 
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domain III of the E protein.  Other receptors implicated in virus attachment are heat 
shock proteins 70 and 90, neolactotetrasylceramide,  CD14, GRP78/BiP, 37kDA/67kDA 
laminin, and C-type lectins such as DC-SIGN, the mannose receptor,  and C-type lectin 
domain family 5 [29]. 
 
Dengue virus particles have been shown through single track analysis to diffuse along 
the cell surface to clathrin coated pits. It is through the clathrin pits that the particles 
are endocytosed. The pits bud and invaginate, developing into a clathrin coated vesicle 
closed by membrane scission by dynamin. Alternative methods of cell entry have been 
documented in mammalian cells, via lipid rafts and caveolae. The virus containing 
endocytic vesicles then lose their clathrin and are delivered to early endosomes. These 
mature into late endosomes. It is from the late endosomes that virus is delivered into 
the cytosol by membrane fusion. Membrane fusion occurs at 10-13 minutes after cell 
infection [29].  
There are a number of mechanisms by which membrane fusion occurs, low-pH induced 
conformational change of the E protein, high cholesterol levels, and use of negatively 
charged lipids. Endosomes have a low-pH; at pH 6.2-6.4 a conformational change occurs 
in the E protein. Protonation of histidine residues are thought to destabilise the DI-DII 
interface. This causes dissociation of E protein rafts and the dimers separate into 
monomers. DII projects outwards exposing its fusion loop to the target membrane. 
Three E proteins form trimers which once stabilised through DI interactions, allows DII 
to fold against the trimer into a hairpin [Fig.6]. The energy released through this 
process causes hemifusion of the outer membrane monolayers with inner membranes 
intact. Following this a fusion pore is formed and the viral capsid is released into the 
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cytosol. It appears that the fusion process is promoted by high cholesterol endosomal 
membranes, by contributing to the low pH environment, but also it seems that DENV 
can interact with a number of lipids. Anionic lipids have been shown to improve the 
efficiency of membrane fusion [29]. 
 
 Fig. 7. Dengue trimer structure  [3] a. Ribbon diagram showing domain I in red, domain 
II in yellow and domain II in blue. Surface representation of the trimer, with the dashed 
grey line indicating the most likely position for the stem.  
 
 
Once released into the cytosol, the nucleocapsid disassembles and the genome is 
transported to the rough endoplasmic reticulum (RER). The precise mechanisms of how 
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this is achieved has not been elucidated. The liberated viral genome has three 
interdependent functions: translation, acting as a mRNA for synthesis of the viral 
polyprotein; replication, acting as a template for the synthesis of further RNA strands; 
and encapsidation, incorporation into new viral particles. Translation commences at the 
5’ AUG codon with the viral cap recuiting the required eukaryotic initiation factors and 
ribosomes. However, capped mRNA is not critical for translation, which suggests that 
cap independent mechanisms of translation may facilitate viral amplication in divergent 
hosts (i.e. mosquitoes and humans). The 3’ stem loop (SL) is able to stimulate 
translation in the absence of viral proteins. Thus it is key to promoting the first round of 
translation. The details of further translation have been poorly established. Following 
translation, a complex of NS3 and its co-factor NS2B act as viral serine protease, 
processing other NS proteins required for replication [23]. 
 
Following translation, the viral NS proteins interact with host factors to form the 
Replication Complex (RC). This results in the production of complementary negatively 
stranded RNA, resulting in an intermediate double-stranded RNA, and finally new 
(+)RNA. This (+)RNA then goes on to function both as mRNA and genomic RNA for the 
viral progeny. Circularization of viral RNA allows coupling of translation and replication 
and occurs on induced cell membranes derived from the ER. Of the NS proteins, NS2A 
seems to direct the RCs to membrane organelles where replication takes place. NS3 and 
NS5 form a complex. These act as an ATPase/helicase and an RTPase, they unwind and 
dephosphorylate the genomic material prior to 5’ capping. NS5 acts as the RNA-
dependent RNA-polymerase (RdRp). RNA synthesis is regulated by sequences within 
the 5’ and 3’ UTRs, the 5’-3’CS and 5’-3’UAR: UAR, CS and cHP are involved with 
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circularization and promotion of RNA synthesis by acting on RdRp. The functions of 
other NS proteins are still being elucidated. Their proposed functions are detailed in fig. 
3 [30]. 
 
Following polyprotein synthesis and genome replication, encapsidation occurs. ER 
derived organelles contain viral RNA-C protein complex and the structural proteins E 
and prM. In immature particles, E and prM proteins are complexed in trimers. During 
virion egress, the particles mature and the E protein forms homodimers. During egress 
the particles pass through the trans-golgi network (TGN) where the prM proteins are 
cleaved by the proteinase furin, stimulated by a low pH environment. pr remains 
associated with the particle until cell release via exocytosis as this prevents premature 
binding of the E protein to the exosomal membrane of the TGN during transit [Fig. 8]. A 
mature virion is composed of one copy of RNA, 90 homodimers of E protein, and 180 
copies of M protein. Cleavage of the prM in the TGN causes the transition from 
immature virus (spiky particles) to infectious mature virus (smooth particles). 
However, cleavage of prM is inefficient and a large number of immature particles are 
produced [29]. 
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Fig.8 Processing of dengue virus in the cell [31]. 1. Fully mature and some partially mature 
infectious viral particles attach directly to a diverse array of host receptors. 2. Virus:immune-
complexes may also attach via Fc receptors. 3. Receptor mediated endocytosis. 4. Acidification 
of the endosomal vesicle induces conformational change in the virion and trimerisation of the E 
protein resulting in release of the nucleocapsid into the cytoplasm. 5. Viral RNA is translated 
into a single polyprotein at the ER. 6. RNA synthesis of anti-sense viral RNA. 7. Newly 
synthesised RNA is packaged by the capsid © protein forming the nucleocapsid. 8. The 
nucleocapsid buds into the ER forming a non-infectious immature particle. 9. Immature viral 
particles are transported through the Golgi where acidification causes exposure of the furin 
cleavage site. Host furin cleaves the pr and M proteins. The now mature viral particle is then 
exported.  
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Fig. 9 Association of prM and E proteins in the immature and mature viral particles  [6]. 
Configuration of the surface viral proteins during maturation of the viral particle. The 
fusion loops are indicated by red stars.  
 
 
Clinical Disease 
The clinical spectrum of dengue is wide, with most infections being asymptomatic 
(approximately 75%) [19]. Approximately 5% of infected patients develop severe 
disease, predominantly affecting children and young adults. After an incubation of 4-10 
days, severe disease has three phases, febrile, critical and recovery [fig. 9] [1]. 
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Fig. 10 Clinical disease course of dengue fever [1]. The diagram shows how the viraemic 
phase of the clinical illness is accompanied by fever, but severe illness develops after the 
viraemia is cleared.  
 
The acute febrile phase, which constitutes the majority of clinical cases, usually lasts 2-7 
days and is accompanied by headache, myalgia, arthralgia, retro-orbital pain, and a 
generalised maculopapular/ petechial rash. At this stage clinical features are 
indistinguishable between severe and non-severe forms of the disease. Patients may 
experience hepatomegaly with raised transaminases, leukopenia and 
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thrombocytopenia. For those who develop severe disease, the critical phase usually 
occurs between days 3 and 7 and coincides with the normalisation of fever. The onset of 
severe disease is usually marked by an increasing haematocrit and rapidly falling 
platelet count. This phase is characterised by a 24-48 hour period of significant vascular 
leak resulting in shock.  Once shock is established, the patient may experience severe 
blood loss with a concomitant fall in haematocrit, hypothermia, organ impairment and 
metabolic acidosis. Other manifestations may include hepatitis, encephalitis and 
myocarditis. Severe dengue is defined by one or more of i) plasma leak that may lead to 
shock and/or fluid accumulation with or without respiratory distress, ii) severe 
bleeding, iii) severe organ impairment. If the patient survives the critical phase, gradual 
re-absorption of the extra vascular fluid occurs over the next few days [1]. 
 
Fig. 11 Dengue case classification and warning signs [1] 
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Risk factors for severe disease 
Dengue pathogenesis is the result of a complex interplay of viral and host factors. 
Development of severe disease is modulated by a range of factors including preceding 
dengue infection, age of the host, genetic background of the host, and viral serotype and 
genotype.  
 
Host determinants 
Experiments conducted in healthy volunteers suggest that infection with one serotype 
confers immunity to that serotype for up to 18 months, but is anticipated to be life-long. 
However, cross-protective immunity to other serotypes is transient, lasting less than 2 
months. Indeed secondary infection is the single most important risk factor for severe 
disease, suggesting that this transient heterologous immunity not only deteriorates, but 
also contributes to disease pathogenesis. From epidemiological studies, we know that 
the incidence of severe disease is much higher in secondary infection with second 
serotype than primary infection. In a Cuban study, of all the cases of DHS/DSS, 95% 
were from secondary infection and 5% were from primary infection. This study also 
showed that infants within the first 6 months of life are at higher risk of severe infection 
than children older than 6 months of age [32]. It is postulated that maternal antibodies 
present in infants creates a scenario where infantile infection mimics the phenotype of 
secondary infection. Antibody responses therefore seem to play an important role. This 
shall be discussed further in the section on humoral immune response.  
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In Cuba, distinct epidemic waves have been carefully documented. It was shown that 
those of African lineage were of decreased risk for severe disease than those of 
European ancestry [33]. This has been corroborated in a number of other Caribbean 
settings [34] [35]. A number of genetic studies have highlighted associations with 
severe disease. Genes identified include: HLA molecules, cell receptors (type 1 
interferons, vitamin D receptor (VDR), intracellular adhesion molecule 3, ICAM3, 
DCSIGN), and blood antigens (platelet antigens and ABO) [36]  [37] [38] [39] [40] [41]. 
Of the HLA polymorphisms identified, few have been verified across different 
populations.  However, HLA-24 has been associated with severe disease in both 
Vietnam and Malaysia [42] [43]. It is felt that the HLA polymorphisms are associated 
with differing T cell induced immunopathology. DCSIGN polymorphisms may have a 
role in disease phenotype as this molecule is a major DENV receptor on dendritic cells. A 
single-nucleotide polymorphism, (SNP) rs4804803, with GG/AG (as opposed to AA) was 
associated with DHF, increased DCSIGN expression and increased cytokine production. 
However counter-intuitively, it was also associated with lower DENV2 viral replication. 
This was reversed by addition of anti-IP10 antibody suggesting that cytokine 
production may interfere with viral replication [40]. 
 
In a study from Vietnam, SNPs at two loci were found to have genome wide associations 
with severe dengue disease. These are MICB, Major Histocompatibility Complex (MHC) 
class I polypeptide sequence B and PLCE1, phospholipase C epsilon 1. The MICB gene 
encodes an inducible activating ligand for the NKG2D type II receptor on NK cells and 
CD8 T cells. The authors postulate that this SNP might be associated with a 
dysfunctional response of NK and or CD8 T cells leading to a higher viral burden and an 
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increased chance of severe disease. Mutations in the PLCE1 gene are also seen in 
nephrotic syndrome, where changes to the glomerular basement membrane of the 
kidney result in proteinuria. It is suggested that perhaps a SNP in the PLCE1 gene may 
cause changes to the vascular endothelium and thus result in plasma leak [44].  
A number of studies have identified other possible risk factors for the development of 
severe disease. These include extremes of age, female gender, ethnicity and co 
morbidities such as diabetes and hypertension [45]. 
 
Viral determinants 
In many parts of the world there is hyper-endemic transmission of dengue with all four 
serotypes co-circulating. Consequently secondary infection, particularly in these 
countries, probably occurs in excess of documented severe disease. Epidemiological 
studies have shown that severe disease may occur in individuals with primary infection 
[32]. Tertiary and quaternary infections have been shown to be responsible for severe 
disease, in Thailand 0.08-0.8% of cases [46], where as in Cuba they account for 17.5% of 
severe cases [47]. 
 
There are a number of viral determinants, which are felt to contribute to severe disease. 
Dengue serotypes 2 and 3 are more often linked with severe disease than 1 and 4 [48]. 
Particular genotypes have been shown to cause severe outbreaks. The most notable 
example is of the serotype replacement in Cuba of the benign Latin American DEN2 
strain with the Asian strain in 1981 and a subsequent increase in the number of severe 
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cases. This correlates with a number of laboratory findings: the Asian strains replicate 
to higher viral titres in dendritic cells [49], they also infect and disseminate to the head 
of A. Egypti mosquitoes more rapidly and in greater proportion than the American 
strains [50]. Genetic analysis of the 2 Asians strains has revealed 6 amino acid changes 
within the prM, E, NS4 and NS5 genes [51]. Mutations within E and NS3 can alter viral 
virulence, perhaps by improving host cell binding, therefore improving viral replication 
efficiency [52]. In Nicaragua, the replacement of DEN2 clade N1 with clade N2, saw an 
increase in the number of severe cases. The new clade was demonstrated to have 
greater replication capacity in vitro, and higher viraemia in patients’ sera. Interestingly, 
waning immunity to DENV1 predisposed to severe disease in those infected with N1 
clade DENV2, whereas waning immunity to DENV3 predisposed to severe disease in N2 
clade DENV2 [53]. 
 
Immune response to dengue 
Innate immune response 
Dermal Langerhans cells (Dendritic cells, DC) are thought to be the initial target cell 
after innoculation by an infected mosquito. The DCs are then activated and migrate to 
regional lymph nodes [54] [30] [55] [26] [56]. The activated DCs then ellicit a IFN/, a 
TNF and a pro-inflammatory response. In the regional lymph nodes, viral replication 
continues and spreads to as yet undefined cells of the macrophage/ monocyte lineage 
where it amplifies [57] [58] [59] [60] [61] [62]. Viraemia follows which may facilitate 
spread to secondary organs such as liver, spleen and bone marrow.   
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Much of the first line of defence against dengue comes from the pattern recognition 
receptors such as Toll-like receptors (TLRs), notably TLR-3, TLR-7, TLR-8, and 
intracellular sensors (e.g. DExE/H box RNA helicases) [63]. These recognise dsRNA, 
ssRNA and modified RNA. TLR-3 is the dominant TLR responder and recognises DNV 
RNA after endsomal acidification. It induces strong IL-8 and interferon α/β (IFN α/β) 
responses [64]. Cytoplasmic helicases, such as retinoic-acid-inducible gene 1(RIG-1) 
and melanoma differentiation-associated gene 5(MDA5),  sense dsRNA in the cytoplasm 
[65] [66]. These sensors are able to differentiate between viral and host RNA (as ribose 
2’-O methylation is only present on host RNA), then signal through the mitochondrial 
antiviral signalling (MAVS) protein on mitochondia and eventually induces the 
transcription of IFN α/β [67, 68] [69]. RIG-1 and MDA5 synergise with TLR-3 to limit 
DENV replication in vitro [66]. 
IFN α/β are able to act in an autocrine manner causing induction of cellular antiviral 
responses, as well as acting on neighbouring cells to warn them of the infection. IFN α/β 
acting through IFNAR (IFN α/β receptor) activate the JAK/STAT pathway resulting in 
production of numerous antiviral proteins and proinflammatory cytokines  [70] [71]. 
The IFNAR signalling also induces alternative signalling pathways such as mitogen 
activated protein kinase p38 cascade and the phosphatidylinositol 3 kinase cascade that 
cause the production of proinflammatory cytokines and chemokines [71]. 
TLR-3 and and cytoplasmic helicases can also induce NFκB, which activates the 
inflammasome causing production of interleukins 1 and 18. These cytokines recruit 
immune cells to the site of infection [72]. 
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Another method of intracellullar defence is via small RNAs (e.g. miRNAs). miRNAs 
interact with proteins in the RNA interference (RNAi) pathway and regulate as well as 
being induced by TLRs and IL-1 signalling [73]. 
The cell has an array of defense mechanisms it uses against dengue virus which includes 
TLR induction of IFN α/β, IFN α/β induction of the JAK/STAT pathway, induction of the 
inflammasome and RNA interference.  
 
Subversion of the cellular antiviral reponse by Dengue virus 
DENV is able to evade the hosts innate immune reponse by sequestration and by active 
subversion of the immune reponse. Dengue virus replicates within the endoplasmic 
reticulum (ER) of cells, whilst there, it is able to rearrange and expand the ER through 
the action of NS2B/3 on X-box binding protein 1 [74]. DENV is also able to reduce the 
unfolded protein response (UPR) to stress, which may prevent or delay host cell death 
during viral replication [74].  It appears that dengue is also able to subvert autophagy 
and lipid metabolism. Autophagy is the process by which cytoplasmic contents are 
degraded. Cytosolic double-membrane vesicles, autophagosomes, engulf cytosolic 
elements and transport them to lysosomes where they are degraded. Dengue, along 
with many other positive-stranded RNA viruses is able to hijak autophagosomes and 
use the machinery to enhance viral replication [75]. It seems that DENV NS3 protein is 
able to increase fatty acid synthesis [76], the lipid droplets then appear to be used by C 
protein as a scaffold for infectious viral particle formation [77]. 
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RNAi 
DENV is able to interfere with RNAi pathways through two mechanisms. NS4B directly 
interferes with Dicer’s ability to process small RNAs in vitro. [73] In addition, sub-
genomic flavivirus RNA (sfRNA), produced from the viral 3’ UTR, is able to inhibit 
cleavage of dsRNA by Dicer by binding to and saturating the RNase [78]. 
IFN α/β pathway abrogation 
Dengue is able to act in multiple ways to interfere with the induction and signalling of 
IFN α/β. Firstly it is able to evade MDA5 recognition of the viral mRNA cap by its 2’-O 
methylation [79] [80] [81]. Next DENV is able to interfer with the downstream 
signalling from RIG-1 and MDA5 , thus downregulating the antiviral response through 
NS2B/3 cleaving MITA/STING [82] [83] [84]. DENV has several ways to interfere with 
the JAK/STAT pathway. NS2A, NS4A and NS4B inhibit STAT1 phosphorylation and 
nuclear translocation [85]. DENV is also able to inhibit IFN α/β signalling by triggering 
the degradation of STAT2 [86]. Indeed, inhibition of IFN α/β and JAK/STAT pathway 
results in increased viraemia in animal models. This is corroborated by clinical studies 
showing that a decrease in the number of plasmacytoid dendritic cells (that are a major 
source of type 1 IFNs), thus mimicing the blockade of IFN production, is associated with 
an increase in disease severity.  
Studies into the overall effect of dengue virus on DCs show that infected DCs undergo 
apoptosis, express a less mature phenotype than surrounding uninfected DCs, produce 
IL-10 (down regulates inflammatory cytokines), and have reduced T cell stimulatory 
capacity [87]. Quite what the cellular mechanisms of this are is not yet known.  
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Fig. 12. Dengue virus lifecycle and the subversion of cellular antiviral reponse [7]. Red 
arrows indicate the dengue virus lifecycle. Tan squares show the subversion of the cellular anti-
viral response. A. Viral maturity can affect infectivity and antibody binding. B. In ADE, infection 
can disrupt TLR, RIG-1, and MDA signalling cascades leading suppression of IFN α/β antiviral 
responses. C. NS 2B/3 cleaves MITA within interferon pathway to downregulate antiviral 
responses. D. Subgenomic RNA and NS4B interfere with RNAi response. E. Dengue induced 
autophagy might enhance viral replication. F. Dengue induces ER hypertrophy. G. NS2A, NS4A 
and NS4B expressed together can inhibit STAT1 phosphorylation and translocation inot the 
nucleus. H. NS5 interferes with IFN α/β signalling by mediating STAT2 degradation via the 
proteosome. 
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NK cell response 
NK cells seem to play a role early in infection to limit dengue replication. In adults with 
mild disease, high number of NK cells along with increased expression of activation 
markers (CD69, CD38, HLA-DR), adhesion molecules (CD11a, CD44), and markers of 
cytotoxic granules (TIA-1) were seen. This contrasts to those with severe disease, who 
had reduced number of NK cells [88]. However, in children, it was shown that NK 
cytotoxicity was increased in patients with severe disease in comparison to those with 
mild disease [89] [90]. In the immunocompetant mouse model A/J, early activation of 
NK and B cells was associated with control of viral load and prevention of disease [91] 
[92]. In experiments in C57BL/6 mice, it was shown that NK cells have site specific viral 
clearance [93]. In particular they showed that early recruitment of NK cells to the liver 
was needed for viral clearance [94]. However, this came at the expense of hepatic cell 
death [95].  
Natural killer cells have also been implicated in antibody-dependent cell-mediated 
cytotoxicity (ADCC). ADCC activity in plasma prior to secondary infection (with either 
DEN-2 or -3) correlated with serotype specific neutralising antibody titres, anti-DENV 
IgG1 levels, and a multitypic PRNT50 pattern [96]. However, this did not necessarily 
correlate clinically. Although high ADCC preceeding secondary DENV-3 was associated 
with lower viraemia, this was not seen with secondary DENV-2.  
These studies suggest that NK cells are involved with early control of viraemia, may be 
involved with cell death related to this control, and may have a role in ADCC.  
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T cell immune response 
The role of T cells in the immunopathology of dengue remains controversial. Severe 
dengue occurs as the virus load falls and cytokine levels increase. This has lead to the 
hypothesis that T cells may drive the immunopathology of severe dengue. T cell 
responses have been identified in both mice and humans. T cell epitopes have been 
investigated and it has been shown that the predominant CD8 T cell epitopes are NS3 
and NS5. These are the largest proteins encoded by the dengue genome and are located 
in the cytoplasm. This may lead to preferential processing and presentation [97].  
 
In acute dengue infection, CD8 response is primarily directed against NS1 and NS5 
dengue proteins, whereas CD4 T cells mainly recognise NS1, E and C proteins [98] [99] 
[100] [101]. Despite this evidence, studies into the kinetics of CD8 responses to acute 
infection showed that levels were absent or very low during the critical phase of the 
illness and peak 2 weeks after the critical phase has passed [102]. Massive T cell 
apoptosis occurs in acute dengue and appears to be greatest in those who have severe 
disease [103] [104]. However, T cells may be sequestered in tissues during the acute 
phase of infection.  
T cell function varies considerable between mild and severe dengue. In mild dengue, 
CD8 T cells have more degraulation  and lower production of inflammatory cytokines. 
However in severe dengue many CD8 cells produce the cytokines TNF and IFN, but 
fail to display degranulation markers. T cell function studies show that the proliferation 
capacity, cytokine production and gene expression show that these functions are 
impaired during severe disease and recover during convalescenc. [105, 106] [107]. 
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The specific role of T cells in the immune response has yet to be established. The intense 
and skewed initial response to infection could be reponsible for driving severe disease. 
However, T cells may control viral replication through protective HLA alleles, but this 
evidence is far from conclusive.  
 
Humoral Immune response 
The make-up of the antibody response has been studied. In acute primary infection, IgM 
response initially dominates, appearing 4-5 days after onset of the illness and lasting for 
approximately 3 months. IgG is produced from about 1 week after onset of illness, 
peaking after several weeks, then declining to low levels but persisting for decades. 
Dengue mainly induces IgG1 and IgG3 responses (which are the subclasses with highest 
affinity to FcR). The antibody response in secondary infection is derived from naïve and 
memory B cells generated in primary infection. In secondary infection, there is a rapid 
IgG response, which commences on the first day of illness. The magnitude of antibody 
response is much greater in secondary infection than in primary. In secondary cases the 
IgM response is variable [108]. 
 
Following the epidemiological studies, it was postulated that the humoral immune 
response might be responsible for severe dengue disease. Ordinarily the interaction of 
virus with antibody leads to viral neutralization. However, it seems that the infectivity 
of some antibody-coated viruses is enhanced if susceptible cells bear Fc receptors. Early 
studies by Halstead in 1977 demonstrated that non-neutralizing anti-dengue antibodies 
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were able to render non-permissive peripheral blood leukocytes (PBLs) permissive to 
dengue infection. They also showed that homotypic anti-dengue antibodies were 
neutralizing at high concentrations, but enhanced at lower concentrations [109]. These 
observations led to the theory of antibody dependent enhancement (ADE). According to 
ADE theory, pre-existing heterologous antibodies, developed during primary infection, 
fail to neutralize virus either because of insufficient avidity or concentration. Instead the 
antibody-dengue immune complexes are then targeted for uptake into cells through Fc 
receptors [110]. ADE has been subdivided into intrinsic and extrinsic phases. The 
extrinsic phase is when there is an increase in the infection of FcR bearing cells and the 
intrinsic phase, where the infection of FcR cells drives an increase in viral production 
through FCR ligation [110]. However, in vivo experiments suggest that ADE does not 
fully explain severe disease pathogenesis. A prospective study showed that pre-dengue 
sera did not correlate with the clinical severity or viral burden of disease [111]. 
 
FcR comprise a multigene family of membrane glycoproteins that aggregate with 
complexed IgG to cause either activatory or inhibitory effects on cellular function. There 
are two FcR associated with dengue, FcRIA and FcRIIA. FcRIA is found exclusively on 
cells of macrophage and dendritic cell lineage and has high affinity for monomeric IgG. 
FcRIIA is broadly distributed through myelogenous cells and has high affinity for 
multimeric IgG.  Rodrigo studied the interaction of dengue with Fc receptors and found 
that antibody bound dengue has enhancing activity broadly through its interactions 
with FcRIIA. However, it didn’t appear to need intracellular signal competency to cause 
its enhancing effects, suggesting that dengue has an as yet undefined alternative 
intracellular mechanism. Interestingly, enhancing effects through FcRIA were 
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dependent on standard intracellular signal pathways [112]. High concentrations of 
weakly neutralizing antibodies form large antibody aggregates that bind to inhibitory 
FcRIIA. However, potently neutralizing antibodies did not form aggregates and did not 
bind FcRIIA [24].  
Monoclonal antibodies and what they have taught us 
Monoclonal antibody work was initially performed using mouse models. In these 
models, mice were immunized with either whole virus or a proportion of the structural 
proteins. Antibodies made to dengue virus were then identified and characterized. In 
mice, a significant proportion of the antibodies produced are to E protein and 
specifically the fusion loop epitope (FLE) and domain III of the E protein. These results 
however, may be skewed by the immunization regimen, which often includes a boost 
with DIII protein. Anti-EDIII antibodies are some of the most potent anti-dengue 
antibodies and achieve 50% neutralization (NT50) in the low picomolar range. Some of 
these antibodies have been used in disease models and have shown efficacy in both 
prophylaxis and treatment of dengue disease [113] [114] [115] [116]. A good example of 
EDIII antibodies is E16, which shows neutralization of West Nile virus in both in vitro 
and in vivo settings and being efficacious at both prophylaxis and treatment [117]. 
However, therapeutic potential of these antibodies is often limited by their serotype 
specificity. Antibodies to the fusion loop appear to bind in a more complex manner. 
They bind more effectively to dengue virus when in the presence of prM. It appears that 
the presence of prM changes the conformation of the virion allowing better access of the 
FLE antibodies to the epitope. As a result, binding and neutralization of dengue virus by 
these antibodies is limited by the concentration of prM, with neutralization titres failing 
to exceed 60-80% even at high concentrations [118].  
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Recent advances in in vitro techniques have meant that human monoclonal antibody 
response has been studied.  Three main techniques have been used. Firstly the use of 
EBV to immortalize memory B cells; secondly single cell sorting, cDNA cloning and 
antibody expression from plasmablast of acutely infected individuals; and thirdly the 
optimization of traditional hybridoma technologies to generate mAbs from memory B 
cells [119]. 
In humans, the memory B cell response appears to be dominated by antibodies to prM. 
In a study by Dejnirattisai, seven patients with secondary dengue infection had their B 
cells screened for reactivity to dengue; monoclonal antibodies from these cells were 
produced. The response was predominantly to prM, 60% of western blot positive 
antibodies, compared to 40% against E [120]. The prM antibodies show poor 
neutralization even at high concentrations, peaking at 30-50%. As prM is not exposed 
on the fully mature virion, these antibodies will only bind to partially mature virions, 
many of which do not have a high enough content of prM to allow neutralization. 
However, they may be sufficient to promote ADE [121].  
Recent studies have found a number of potently neutralising monoclonal antibodies. 
These antibodies share the characteristic of binding across more than one E protein, to 
conformational and quaternary structures. These include 5J7 (DEN3), CR4354 (to West 
Nile) and HM14c10 (to DEN 1) [122] [123] [124]. Interestingly, 5J7 is strongly 
neutralising, but specific to dengue 3. Analysis of its binding suggests that this serotype 
specificity derives from the charges of the amino acids in its binding sites. This 
highlights the difficulty in designing effective vaccines against dengue; that changes in 
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amino acids between serotypes results in quite different epitope binding site, and many 
of these conformational antibodies are serotype specifics.  
 
Studies from Dejnirattisai and Rouvinski have found a novel epitope, envelope dimer 
epitope (EDE).  The antibodies bind to the basic repeating envelope dimers making up 
the virion surface. X-ray crystallography has indentified two distinct epitopes, EDE1 and 
EDE2. These epitopes map to the binding site between prM and E proteins and is highly 
conserved. Neutralising antibodies binding at this site are broadly neutralising (bnAbs) 
across serotypes. However, antibodies cannot bind to the EDE if the virus is 100% 
immature. This is because the EDE is only formed as the viral particle is maturing. The 
bnAbs identified in these studies have such a high affinity they are able to outcompete 
uncleaved prM on partially immature virions from their interaction with E dimers [125] 
[118].  If vaccine design was able to incorporate the EDE as a target, it could potentially 
allow a broadly neutralising antibody response across serotypes that also generates 
antibodies that may out compete enhancing antibodies. The following table (Table 1) 
outlines the studies of mAbs produced to dengue.  
 
 
Summary 
The immune reponse to dengue is complex and varies according to not only the stage of 
infection, but also whether the infection is primary or secondary. Understanding the 
immune response to dengue is key not only to our understanding of the disease, but 
also to vaccine design. Vaccine studies to date have proved that finding a safe and 
efficacious vaccine to all four serotypes similtaneously  is difficult. If we can understand 
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the drivers of productive and deleterious immune responses, this can inform further 
vaccine work.  
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Table 1. Summary of studies investigating monoclonal antibodies 
Author Year  Mouse 
human 
1’/2’ 
Acute/ 
convalescent/ 
mouse 
DEN 
subtype 
mAb Neutralising? ADE? Therapeutic studies 
Studies assessing breath of antibody reponse 
(Setthapramote
, Sasaki et al. 
2012) 
2012 H 4 acute 
secondary  
5 early 
convalescent  
2 
?St 
Acute: E 81%, prM 6.6% NS1 
3.3%; cross react all 4 st 
Conv: E 13.3%, prM 13.3%, 
NS1 53.3% 
NT NT 
(Beltramello, 
Williams et al.)  
2010 H Late 
convalescent 
3pt 1’  
2pt 2’ 
 
 
2,3,4 
1 & 2 
EDIII most potent neut, neut 
3-4 DEN St, less abundant in H 
repertoire than M 
EDI/DII less potent neut, more 
St cross react than DIII 
prM low neut  
 
prM high 
ADE even 
at high 
conc 
3mAb with potent neut 
that use 2 epitopes to 4St 
engineered with LALA 
variant to prevent FCyR 
binding, protected against 
lethal infection in mice 
(de Alwis, 
Smith et al.) 
2012 H 1’ Convalescent  
 
1pt D2, 
1pt D3 
most mAbs broadly St cross 
reactive, weakly neut and 
recognised prM 
NT NT 
(Friberg, 
Jaiswal et al.) 
2012 H Late 
convalesent 1’ 
(1Pt) 
3 50% rE or NS1 NT NT 
(Shrestha, 
Brien et al.) 
2010 M M vaccinate 
with D1 
D1 Gt2 79mAb 
16 strong neut Gt2 all bind 
EDIII 
2 (E105 E106) strong neut all 
5Gt of D1(bound BC loop) 
Sequence variation did not 
fully explain neut 
 
NT NT 
 
 46 
mAbs to E protein 
Dejnirattisai, 
Wongwiwat et 
al [118] 
2015 H Acute 2’ 
infection 
? 145 mAbs generated, 83 
bound E, 46 bound to 
fusion loop epitope. 
mAbs also bound across 
E dimer  at EDE  1 &2. 
EDE 1&2 mAbs 
neutralised DENV2 to 
>80% of DC and C6/36 
derived virus 
ADE 4-8x less 
with EDE mAb 
vs FLE mAb 
NT 
Smith, de Alwis 
et al [116] 
2013 H Late 
convalescent 
2’ infection  
? 1C19 to DII fusion loop 
(aa 93-97) bc region. 
Ultrahigh potency, neut 
all 4 serotypes, competes 
for binding with other 
mAbs 
NT Reduced viraemia in mice 
Sasaki, 
Setthapramote 
et al [126] 
2013 H Acute 
secondary 
infection 2pt 
(1DF, 1DHF) 
Early 
secondary 
convalescence 
(2wk)(5pt) 
2 Acute samples: 17 mAbs 
strong neut to all 4st 
13/17 against DII (53-
132) 
E conva: no mAb to neut 
all 4 serotype 
 
No diff ADE 
between DF and 
DHF 
mAb protected mice from 
lethal infection 
Costin, Zaitseva 
et al [115] 
2013 H Early conv 1’ 
Convalescent 
1’ 
Early conv 2’ 
? 3mAbs: 4.8A, DIIC, 1.6D 
(1 each pt) high neut E 
protein (DI/II98-109). 
Inhibit virus endosome 
fusion 
All mediate ADE 
at low conc 
NT 
Schieffelin, 
Costin et al 
[127] 
2010 H 2yr conv ? 3 IgG1 mAb to E 
All bound 2/4 st, 1 mAb 
neut 3 st 
All cause ADE NT 
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De Alwis, Smith 
et al [128] 
2012 H 8pt late conv ? 
1’/2’ 
2/3 IF4, 5J7, 2D22 neut single 
st  
Bind quaternary 
structure. 2D22 by 
blocking fusion  
[fibrinisah 2015] 
NT NT 
Saokaew, 
Poungpair et al 
[129] 
2014 H  Manufactured 
H single chain 
variable 
fragment 
(Scvf) to EDIII 
- 15A: Neut D1,2,4 not 3 NT NT 
Williams, 
Sukupolvi-
Petty et al 
[130] 
2013 H/M 
chimer
a 
E60 MmAb to 
WNV E prot 
87.1 human 
Mab modified 
with LALA 
 E60 N297Q & 87.1 LALA 
neut 
Protective 
following Ab 
enhance 
infection  
? compete with enhancing 
Ab in mouse model 
protecting against lethal 
disease 
Yamanaka, 
Kotaki et al 
[131] 
2013 M D1 Mochizuki 
strain immm 
mice, 26 mAb 
 MAb  
7F4 to DII: strong neut  
3H12 
 
7F4: No ADE 
3H12: 
enhancing 
NT 
Li, Liao et al 
[132] 
2012 M 17 Mmab to E D2 Humanised DB32-6 bind 
EDIII at K310 
Strong neut 
No 
enhancement 
NT 
Midgley, 
Flanagan et al 
[133] 
2012 M EDIII imm 
mouse 
D2 2H12 cross reactive D1-4 
binds AB loop DIII 
No 
enhancement 
NT 
Cockburn, 
Navarro et al 
[134] 
2012 M ?  Fab 4EII neut D1-4 binds 
DIII 
NT NT 
Zhou, Austin et 
al [135] 
2013 M ? 3 mAb 8A1 binds EDIII 
variable neut to D3 
NT NT 
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Leon-Juarez, 
Garcia-Cordero 
et al [136] 
2013 M D2 E prot imm 
mice 
 No neut observed NT NT 
Deng, Dai et al 
[137] 
2011 M D2 imm mice  2A10G6 neut 1-4, YFV, 
WNV binds to tip of 
fusion loop 
(98DRXW101) 
NT NT 
Sukupolvi-
Petty, Austin et 
al [138] 
2010 M D2 imm mice  Protective mAb 
generated to DI dimer 
interface, DII lat ridge & 
fusion loop, DII lat ridge 
& A strand 
NT In vitro neut correlated 
with in vivo 
Rajamanonman
i, Nkenfou et 
al[139] 
2009 
 
M rDIII imm mice  ScFv 9F12 prevents viral 
entry. No neut tests 
NT NT 
Puttikhunt, 
Keelapang et al 
[140] 
2008 M D2 imm mice  2E11 detects 
conformational prM-E 
heterodimer 
NT NT 
mAbs to prM protein 
Luo, Feng et al 
[141] 
2013 H From 
hybridoma 
 4D10 poor neut D1-4 Potent enhance 
(aa14-18 pRM) 
NT 
Dejnirattisai, 
Jumnainsong et 
al [120] 
2010 H 1pt D1, 4Pt D2, 
1Pt D4 early 
convalescent 
 Anti-prM dominant mAb 
(60% vs E 40%). Poor 
neut 
enhance NT 
Wang, Li et al 
[142] 
2013 M Hybridoma  2H2 inhibits maturation 
virus at high conc (3Fab 
to each spike) low conc 
(2Fab to each spike) 
NT NT 
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Key 
Conv= convalescent, D1= dengue 1, D2= dengue 2, D3= dengue 3, D4= Dengue 4, DF= dengue fever, DHF= dengue haemorrhagic fever, 
DC= dendritic cell, EDE= Edimer dependent epitope, FLE= Fusion loop epitope, H= human, M= Mouse, neut= neutralising, NT= not 
tested, St= serotype. 
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Hypothesis 
Severe dengue disease may be augmented by naturally occurring antibodies. These 
antibodies may be produced in primary disease as well as secondary disease. 
 
 
Aims 
Although the majority of cases of severe dengue occur in patients with secondary 
disease, severe disease may occur in those with primary disease. In these cases, the 
immune system has not been primed to dengue. Therefore a primed immune response 
cannot be the full explanation of the cause of severe disease. Understanding the immune 
response to severe primary disease will shed light not only on the mechanisms of severe 
disease, but will be instructive in safe the development of vaccines.  In this study, I will 
investigate the IgG response of a patient with acute severe primary dengue.  
 
1. I will assess the development of IgG antibodies at the early time point of day -1 
pre-defervesence (timepoint at which the fever normalises).  
2. I will assess the nature of the antibodies.  
a. Whether the antibodies are serotype specific or cross reactive 
b. Which epitopes the antibodies react against  
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Materials and Methods 
 
Materials 
Primers and vectors 
Primers used for the nested PCR and outlined in table. Vector sequences for pIgγ1, pIgκ 
and pIgλ can be found at NCBI GenBank (accession numbers: FJ475055, FJ475056, 
FJ475057). 
Table 2. Nested PCR primer sequences 
Name 5’  3’ sequence 
Nested PCR for the Heavy Chain 
5' AgeI VH1/5 CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG 
5' AgeI VH3 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG 
5' AgeI VH4 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG 
5' AgeI VH3-23 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG 
5' AgeI VH4-34 CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG 
5' AgeI VH 1–18 CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG 
5' AgeI VH 1–24 CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG 
5' AgeI VH 3–9/30/33 CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG 
5' AgeI VH 6–1 CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG 
5′ AgeI VH4–39 CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG 
5′ AgeI VH1 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG 
5′ AgeI VH3–33 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG 
3' SalI JH1/2/4/5 TGCGAAGTCGACGCTGAGGAGACGGTGACCAG 
3' SalI JH3 TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG 
3' SalI JH6 TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG 
Nested PCR for the Kappa Light Chain 
5' Pan VK ATGACCCAGWCTCCABYCWCCCTG 
3' CK 494 GTGCTGTCCTTGCTGTCCTGCTC 
5' AgeI VK1-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC 
5' AgeI VK1-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT 
5' AgeI VK1D-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC 
5' AgeI VK2-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC 
5' AgeI VK2-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC 
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Media and Buffers 
Table 3. Media recipes 
Medium or buffer Recipe 
Blocking Buffer 5% (w/v) milk in 1x PBS 
D-10 medium 
DMEM; 10 % FCS; 100 units/ml penicillin, 100 μg/ml streptomycin; 2 mM L-
Glutamine 
PBST 0.1% Tween-20 in 1x PBS 
1 x PBS 
1 mM KH2PO; 10 mM Na2HPO4; 137 mM NaCl; 2.7 mM KCl; pH 7.4; Sterilised by 
autoclaving. 
Carbonate Buffer 
1 tablet of Carbonate-Bicarbonate Buffer (Cat. no. C3041) dissolve in 100 ml 
distilled water 
PNPP solution p-Nitrophenylphosphate (Biorad, Cat 172-1063) 
1 x Running Buffer 25 mM Tris; 250 mM Glycine; 0.05 % (w/v) SDS 
1 x Transfer Buffer 20 % Methanol; 47.9 mM Tris; 38.6 mM Glycine; 1.28 mM SDS 
 
5' AgeI VK3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC 
5' AgeI VK3-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC 
5' AgeI VK3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT 
5' AgeI VK4-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC 
3' BsiWI JK1/2/4 GCCACCGTACGTTTGATYTCCACCTTGGTC 
3' BsiWI JK3 GCCACCGTACGTTTGATATCCACTTTGGTC 
3' BsiWI JK5 GCCACCGTACGTTTAATCTCCAGTCGTGTC 
Nested PCR for the Lambda Light Chain 
5' AgeI Vλ1 CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG 
5' AgeI Vλ2 CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG 
5' AgeI Vλ3 CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG 
5' AgeI Vλ4/5 CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA 
5' AgeI Vλ6 CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG 
5' AgeI Vλ7/8 CTGCTACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG 
3' XhoI Cλ CTCCTCACTCGAGGGYGGGAACAGAGTG 
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Table 4. Primary and secondary antibodies 
Antibody Organism Origin Method Dilution 
Primary Antibodies 
anti-human IgG mouse Sigma ELISA 1:10 000 
anti-prM 1H10  mouse in-house isolation ELISA/Dot blot 
5 μg/ml / supernatant 
from transfected cells 
anti-E 4G2  mouse in-house isolation Dot blot 
Supernatant from 
transfected cells 
Secondary Antibodies 
anti-human IgG 
(Fc) alkaline 
phosphatase 
conjugate 
goat Sigma ELISA 1:10 000 
anti-human IgG 
HRP 
rabbit Dako 
Dot blot/Western 
Blot 
1:1000 / 1:1000 
anti-mouse IgG 
HRP 
goat Dako Dot blot 1:1000 
 
 
 
 
 
 
 
 
 54 
Table 5. Dengue virus strains used 
 
 
 
 
 
 
 
Methods summary 
 
Activated B cells were isolated from a patient with acute dengue virus. Recombinant 
monoclonal antibodies were then produced from the activated B cells. These mAbs were 
then assessed for: their ability to recognise dengue and Japanese encephalitis virus; 
which epitopes on the dengue virus they recognised; which amino acids of the 
structural proteins they bind to; and whether they inhibit or enhance infection. 
 
 
Patient 
 
Acute dengue infection was diagnosed clinically and confirmed by identification of the 
virus by RT-PCR. Disease severity was assessed by WHO criteria [1].  Ethical approval 
was provided by Siriraj, Khon Kaen and Songkhla hospitals, Thailand. The sample was 
taken at day -1, defined by defervescence of fever, i.e. the sample was taken the day 
before the fever resolved. 
 
 
DENV serotype DENV strain 
Serotype 1 Hawaii 
Serotype 2 16681 
Serotype 3 H87 
Serotype 4 H241 
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Table 6. Dengue patient details 
 
 
Isolation of cells 
Whole blood is collected from the patient at defervescence (day -1). Peripheral blood 
mononuclear cells (PBMCs) are isolated using standard protocol. 8ml of blood was 
mixed with 16l heparin. The blood was centrifuged at 3000g for 10 minutes; following 
this the plasma layer was removed. RPMI (PAA) was then added to the remaining blood 
to be made up to 15ml. This was layered over 15ml Lymphoprep (Axis-Shield). The 
samples were then centrifuged at 800g for 30minutes. The PBMC layer was removed 
and diluted in 50ml RPMI then centrifuged at 800g for a further 10 minutes. The 
supernatant was discarded and the cells resuspended in 50ml RPMI, centrifuged at 
360g for 10 minutes and then this was repeated for a further spin at 600g for 5 minutes. 
[119] [119, 143] 
 
Activated B cells are then sorted by flow cytometry  
1 million cells were resuspended in 1ml of 10% FCS in RPMI (R-10); these cells were 
used for sorting. As controls, 0.5 106 cells were aliquotted for each fluorophore to be 
tested and one aliquot remained unstained.  Centrifuge at 2000rpm for 5 minutes.  
 
Activated B cells were selected by adding for the following antibodies (for staining 1x 
106 cells): 4l anti-CD3 PerCP (245766, BD); 4l anti-CD27 FITC (555440, BD); 4l anti-
CD38 APC (555462, BD); 4l anti-CD20 PerCP (245794, BD); 1l anti-CD19 PE (R 0808, 
Dako) in 50l FACS buffer. Controls were prepared by adding each of the fluorophore-
conjugated antibodies to each control aliquot 
Patient ID Clinical Diagnosis Type of infection Serotype Time of sample 
1-0623-3 DHF-1 Primary DENV 1 Day -1 
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Cells were incubated for 30 minutes on ice, then washed with 2ml FACS buffer and 
centrifuged at 2000rpm for 5mins. The cells were resuspended in 300-500l of FACS 
buffer.   
 
The cells were gated CD19+/CD20-/CD3-/CD27high/CD38high 
 
Antibody secreting cells (ASC) are then separated as single cells in a 96 well plate 
coated with 10l of RNase inhibitor buffer (5ml RNase-free water, 50l 1MTris pH8 and 
125l RNasin). Cells were sorted and frozen immediately on dry ice to -80c [119] [8]. 
 
RT-PCR for immunoglobulin chains (heavy, lambda and kappa) 
The PBMCs were thawed and 15l RT-PCR master mix was added directly to them. 
Master mix was made from One-step PCR kit (Qiagen) and was made up as follows for 1 
reaction: 5l buffer, 1l of  forward primer (from stock containing 10l each of 100M 
L-VH1, L-VH3, L-VH4/6, L-VH5, L-VK1/2, L-VK 3, LVK4, L-Vλ1, L-Vλ2, L-Vλ3, L-Vλ4/5, L-
Vλ6, L-Vλ7, L-Vλ8), 1l of reverse primer (from stock containing 10l each CγCH1, 
CK543, Cλ plus 70l water), 1l dNTP, 6.5l water, 0.5l enzyme mix. Primers were 
designed to cover all variable genes. Master mix was added to empty wells for negative 
controls and to 0.7g RNA from the B cell clone 3-147 for the positive control.  [119] [8] 
Cycling conditions were: 30 min 50c; 15mins 95c; 50 cycles of 30 secs 94c, 30 secs 
58c and 1 min 72c; followed by 10mins 72c.  
 
Nested PCR for amplifying heavy and light chain V genes   
Master mix was made using HotStarTaq kit (Qiagen): 4l HotstarTaq buffer, 1l forward 
primer (10M Heavy chain: 5’AgeI VH mix, Lambda chain: 5’AgeI Vλ mix, Kappa chain: 
PanVκ) 1l reverse primer (10M Heavy chain: 3’SalI JH mix, Lambda chain: CλXhoI, 
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Kappa chain: Cκ494), 0.5l dNTP (25M), 0.25l HotstarTaq enzyme and make up to 
40l with water. Master mix was then aliquotted, 37l, and 3l RT-PCR product [119] 
[8]. PCR cycling conditions were: 15mins 95c; 50 cycles of 30 secs 94c, 30 secs 58c, 
45 secs 72c; then 10min 72c.  
 
PCR purification 
Gel loading dye was added to each PCR product and then these were loaded onto a 1% 
agarose gel in TBE buffer for electrophoresis. And run for 30mins at 100V. Products 
were analysed under UV light. Products were approximately 380bp heavy chain, 400bp 
lambda chain, 540bp kappa chain. DNA bands were excised from the gel and purified 
using QIAquick gel extraction kit (Qiagen) [119] [8]. 
 
Kappa chain sequencing 
Kappa chain PCR product was sequenced directly using the reverse primer Ck494 by 
the in-house sequencing service using single primer extension. Sequence data analysed 
to determine which cloning PCR primer to use from the 5’ Agel VK spec and 3’ BsiWI JK 
spec group. 
 
Cloning PCR for kappa chains 
Master mix was made using HotStarTaq kit (Qiagen): 4l HotstarTaq buffer, 1l forward 
primer, 1l reverse primer, 0.5l dNTP (25M), 0.25l HotstarTaq enzyme and 40l 
water. Master mix was then aliquotted, 37l, and 3l RT-PCR product. Forward and 
reverse primers as determined by sequencing.  
 
PCR cycling conditions were: 15mins 95c; 50 cycles of 30 secs 94c, 30 secs 58c, 45 
secs 72c; then 10min 72c.  
 
 58 
Gel loading dye was added to each PCR product and then these were loaded onto a 1% 
agarose gel in TBE buffer for electrophoresis. And run for 30mins at 100V. Products 
were analysed under UV light. Products were approximately 350bp  [119] [8]. 
 
Expression vector cloning 
Purified PCR products of heavy and light chains were digested with matching restriction 
endonucleases and buffers as recommended by the supplier (NEB). Heavy chain: 45l 
nested PCR product, 0.125l Agel-HF, 2l Sal1-HF, 5l NE Buffer 4, 0.5l BSA. Digest for 
6 hours 37c. Lambda chain: 45l nested PCR product, 0.125l Agel-HF, 0.5l XhoI, 5l 
NE Buffer 4, 0.5l BSA. Digest for 6 hours 37c. Kappa chains: 45l 2nd round, cloning 
PCR product, 0.125l Agel, 5l Ne Buffer 4, 0.5l BSA. Digest for 3 hours at 37c. The 
add 0.5l BsiWI. Digest for 3 hours at 55c. Reactions were purified using QIAquick kit 
(Qiagen).  
Human expression vectors pIgγ1, pIgκ and pIgλ were used. The vectors contained a 
multiple cloning site, HCMV promoter, amp resistance gene, leader sequence and 
constant region sequence for either IgG1 C, C, C.  
The vector was digested by matching restriction enzymes as above: vector 3mcg, 7l 
buffer, 7l BSA, 1l enzyme 1, 1l enzyme 2, plus SDW to make up. This was incubated 
overnight at 37c. The restriction enzymes were heat inactivated at 65c for 20mins. 
Vector DNA was dephosphorylated with 1 unit CIP (calf intestinal phosphatase) (NEB) 
per 1mcg vector and incubated for 1 hour at 37c.  
Vectors were purified by running on a 1.5% agarose gel in TBE buffer and run for 
30mins at 100V. DNA bands were excised from the gel and purified using QIAquick gel 
extraction kit (Qiagen).  
 
Digested PCR products were inserted into the expression vector. Vector and insert were 
added at a 1:3 molar ratio, 2l ligase buffer, 0.5l T4 ligase (200 units) (NEB), reaction 
volume of 20l at 16c for 16 hours.  
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10l of the ligated vector was used to transform 100l competent DH5 E. coli. Vector 
plus insert were added to the DH5 E. coli on ice and incubated for 30mins, they were 
then incubated at 42c for 30secs and returned to ice for 3mins. 1ml of LB broth was 
added to each aliquot and incubated for 1 hour at 37c 220rpm. The transformed E. coli 
was pelleted, resuspended and was plated onto LB agar plus 50g/ml ampicillin and 
grown overnight at 37c. 3 small colonies were picked for each chain, and inoculated 
into LB broth and incubated at 37c overnight. DNA was extracted using QIAPrep spin 
kit (Qiagen). DNA was sequenced using single primer extension sequencing. The primer 
IgGint anneals within the C region of the vector allowing reading of the sequence of the 
vector and insert [119] [8]. 
 
Antibody expression by 293T cells 
293T cells were seeded at 2x105 cells per well (24 well plate) and grown to 50-80% 
confluency in D-10 at 37 c, 5% CO2.  60l DMEM was aliquotted. To this 1l of heavy 
chain DNA, 1l of light chain DNA and 3l PEI was added. This was incubated at room 
temperature for 15 minutes then added to the 293T cells. The 293T cells were 
incubated at 37 c, 5% CO2 for 24 hours, washed and media changed to Ultra-DOMA 
protein-free media (Biowhittaker) with 50units/ml penicillin and 50g/ml 
streptomycin. Cells were then incubated for 4 days at 37c, 5% CO2 and the antibody 
supernatant was harvested. The supernatant was pelleted at 2500rpm for 5 mins and 
stored in the fridge [119]. 
 
 
 
Fig. 13 Summary of mAb production. Adapted from [8] Heavy and light chains are 
produced by RT PCR and then amplified using a nested PCR. The DNA produced is then 
ligated into an expression vector. The vector was used to transform competent E. coli , 
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which then produced large volumes of DNA. The DNA form heavy and light chains was 
co-transfected into 293T cells, which then produced the immunoglobulin chains.  
 
 
Anti-human IgG ELISA 
Concentration ELISAs were performed. 96 well ELISA plates were coated with mouse 
anti-human IgG at a dilution of 1:10 000, 50l per well and incubated overnight at 4c. 
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The plates were washed 3 times with 200l PBS-T (PBS plus 0.05% tween). Plates were 
blocked with 200l BSA blocking solution (PBS plus 3% BSA) for 1 hour at room 
temperature. The plates were washed 3 times with 200l PBS-T. Antibody supernatant 
from transfection was then added to the wells at concentration of neat, 1:150, 1:600, 
and incubated for 1 hour at 37c. As a standard serial 2-fold dilutions of IgG from human 
serum was used starting at 1mg/ml. Negative controls were blocking buffer alone. The 
plates were washed 3 times with 200l PBS-T. 50l of 1:10 000 secondary antibody 
(anti-human IgG AP (Fc specific)) was added per well. The plates were incubated for 1 
hour at 37c, then 50l of PNPP was added to each well and incubated at room 
temperature in the dark. The absorbance was read at 405nm on a Biorad ELISA plate 
reader after 30 and 60 minutes incubation. A standard curve was produced using the 
known concentrations of IgG from serum. Concentrations of antibodies were calculated 
from the trend line equation.  
 
 
DENV dot blot 
 
A dot blot was performed to assess whether the recombinant antibodies produced 
bound to DENV1-4 and/or JE [144] [145]. 
 
Supernatant from virus-infected C6/36 cells was inactivated with UV. The supernatant 
of DENV 1,2,3,4 and JE and non-infected mock were dotted onto nitrocellulose 
membranes. Membranes were allowed to dry and then added to PBS with 5% milk to 
block for 60 mins at room temperature. Membranes were washed 3 times with PBS-T. 
The primary antibody samples were cell supernatant from antibody transfection was 
diluted in 5% skimmed milk, with controls being anti-prM and anti-influenza. 100l of 
primary antibody was added to each membrane strip and incubated at 4c overnight. 
The membranes were washed with 3 times with PBS-T. Secondary antibody, anti-
human rabbit IgG HRP (P0214) at a dilution of 1:1000 in 5% skimmed milk was added, 
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100l per membrane strip. The membranes were incubated at room temperature in the 
dark for 1 hour. The membranes were washed with 3 times with PBS-T and membranes 
were developed using luminata Classico Western HRP substrate 80l per membrane 
and exposed on photographic film (Kodak).  
 
DENV Western blot 
Western blot was performed to assess which structural dengue protein the recombinant 
antibodies bound to [144] [145]. 
 
Lysate from DENV infected C6/36 cells was treated with 1% TritonX-100 in PBS and UV 
inactivated. Negative control was prepared as above but from non-infected C6/36 cells. 
The lysate was centrifuged at 8000g for 10minutes and the supernatant was added to 
non-reducing loading dye. This was loaded onto a 12% SDS gel and run at 100v for 5-10 
minutes, then 120v for 90 minutes. The gel was then blotted onto a nitrocellulose 
membrane in transfer buffer at 0.05A/gel for 1 hour. The membrane was washed twice 
for 10 minutes in PBS and air dried. The membrane was cut into strips and probed with 
the recombinant antibody and controls. Recombinant antibody was prepared in a 1:2 
dilution in 5% skimmed milk. Controls were: positive control sample, NS1, prM and 
negative; anti-influenza. 60l of antibody was added to each membrane strip and 
incubated at 4c overnight. The membranes were washed 3 times with PBS-T and then 
probed with 65l of the secondary antibody, anti-human rabbit IgG HRP (P0214) at a 
dilution of 1:1000 in 5% skimmed milk. The membranes were incubated for an hour at 
room temperature and then washed 3 times with PBS-T. The substrate, luminata 
Classico Western HRP (WBLUCO100), was added at 65l per membrane and incubated 
for 3 minutes at room temperature, then exposed on photographic film (Kodak).  
 
VLP alanine scan library production 
Virus-like particles (VLPs) are shell like particles made up only of the structural 
proteins. Dengue constructs have been made with a combination of the three structural 
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proteins (E, prM and C). Using VLPs allows changes to be made to the structural 
proteins easily and outside of the category 3 laboratory. We use constructs from E and 
prM as: prM is necessary for post-translational modification of E protein; immature 
viral particles are frequently produced with prM still visible on the external viral 
particle [146] [9]. 
 
An alanine scan was performed to assess key binding residues of the mAbs. Site-
directed mutagenesis was performed such that each amino acid of the E and prM 
proteins is replaced with an alanine amino acid. Alanine is chosen as it is small and 
chemically inert, so eliminates side chain interactions, but is able to mimic secondary 
structure preferences of many amino acids [147]. However, some of the mutations 
introduced may affect production or excretion of the VLP. 
 
Fig. 14. Diagram of VLP production. Adapted from [9] prM and E DNA sequences are ligated 
into competent E. coli. The DNA produced is then used to transfect 293T cells. The 293T cells 
produce prM and E proteins packaged as VLPs. 
 
 
 
 
 64 
Primer design and site directed mutagenesis 
Primers to include the alanine substitutions were designed using Quikchange primer 
design software (http://www.genomics.agilent.com/primerDesignProgram.jsp). The 
primers were then diluted 1:10 with SDW to create a stock. A cloning PCR was 
performed. Primers were diluted a further 1:10. Master mix: 5l buffer, 0.5l forward 
primer, 0.5l reverse primer, 2l dNTP (10mM), 0.5l magnesium sulphate, 7.5l 10x 
enzyme, 0.25l Pfx, 8.3l SDW, 0.5l template (DEN1 prME wild type). Master mix was 
then aliquotted, 25l per sample. PCR was performed for 16 cycles at 94°C for 1 min, 
57°C for 1 min and 68°C for 7 min. 
 
PCR products were run on a gel to confirm the PCR product. Gel loading dye was added 
to 5l of each PCR product and then these were loaded onto a 1.5% agarose gel in TBE 
buffer for electrophoresis. And run for 30mins at 100V. Products were analysed under 
UV light. The remainder of the PCR product was purified using QIAquick kit (Qiagen). 
 
Dpn1 digestion was then performed to eliminate template DNA: 32l PCR product, 3.4l 
10x buffer 4, 0.5l Dpn1. This was incubated overnight at 37c. This was followed by 
heat inactivation of Dpn1 for 20 minutes at 65c, and then cooled on ice. The product 
was then used to transform competent DH5 E. coli and plated out as described above. 
Three small colonies were picked from each plate and inoculated into 1.2ml of Terrific 
broth with ampicillin 75 μg/ml and incubated overnight at 37c 220rpm. DNA was 
extracted using Quicklyse (Qiagen). Product DNA was sent for sequencing and then 
analysed (using http://www.ebi.ac.uk/Tools/st/emboss_transeq/) to assess alanine 
insertion. If any samples had failed, new colonies were picked from the plates and 
assessed.  
 
E coli colonies with the correct alanine substitution inserted, were regrown in 10mls LB 
broth overnight at 37c 220rpm. Glycerol stocks of the E coli were prepared using 250l 
50% glycerol and 583l E coli, placed on ice, and then frozen to -80c. The remainder of 
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the E coli was centrifuged at 3000rpm for 10minutes, broth discarded and DNA 
extracted using miniprep (Qiagen).  
 
 
VLP expression by 293T cells 
293T cells were seeded at 2x105 cells per well (24 well plate) and grown to 50-80% 
confluency in D-10 at 37 c, 5% CO2.  60l DMEM was aliquotted. To this  1l of VLP DNA 
and 3l PEI was added. This was incubated at room temperature for 15 minutes then 
added to the 293T cells. The 293T cells were incubated at 37 c, 5% CO2 for 6 hours, 
washed and media changed to Ultra-DOMA protein-free media (Biowhittaker) with 
50units/ml penicillin and 50g/ml streptomycin and glutamine. Cells were then 
incubated for 5 days at 37c, 5% CO2 and the antibody supernatant was harvested. The 
supernatant was pelleted at 2500rpm for 5 mins and stored in the fridge.  
 
Concentration ELISA 
An ELISA to determine to concentration of the VLP produced relative to WT was 
performed.  
 
96 well ELISA plates were coated with anti-prM IgG (1H10) 5g/ml in 50l carbonate 
buffer and incubated overnight at 4c. The plate was washed 3 times with 200l PBS-T 
and blocked with 200l blocking solution (3% BSA in 1x PBS). The plates were 
incubated for 1 hour at room temperature and washed 3 times with PBS-T as before. 
50l of each VLP mutant was added to wells at concentration of neat, 1:4, 1:16 and 1:32 
and incubated for 1 hour at 37c. The plates were washed as before. 50l of mixed 
antibody [table 7] (designed to bind to either E or prM) were added to each well and 
incubated for 1 hour at 37c plates were washed again as previously and 50l of 
secondary antibody was added, IgG AP goat anti-human (A9544) at a dilution of 1:10 
000 in BSA blocking solution. The plates were incubated for a further hour at 37c, 
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washed with PBS-T and 50l PNPP added to each well and incubated at room 
temperature in the dark for 30/45/60 minutes.  Plates were read at 420nm Biorad 
ELISA plate reader.  
 
Table 7. In house anti- E and prM antibodies 
 
Antibody Origin 
[c] 
(μg/ml) 
749(2)A7_H2 in-house isolation 50.084 
751-C5_H in-house isolation 29.42 
751-C10_H in-house isolation 65.132 
753(3)B11_H1 in-house isolation 703.532 
 
 
Dot blot of VLP  
A dot blot of the VLP produced was performed to assess whether the alanine 
substitutions affected ability of the VLPs to bind to prM and E. 
 
2l of supernatant of the VLPs from 293T cells was dotted onto a nitrocellulose 
membrane and allowed to air dry. The membranes were soaked in 5% skimmed milk in 
1x PBS for 1 hour. The membranes were then washed 3 times in PBS. Primary antibody 
was added, either anti-prM (1H10) or anti-E (4G2), 1.5mls per membrane and 
incubated for 2 hours at room temperature. The membranes were washed 3 times in 
PBS-T for 5 mins each. Secondary antibody was then added to each membrane, anti-
mouse polyclonal goat HRP (P0447) 1:1000 dilution in skimmed milk PBS, and 
membranes incubated for 1 hour at room temperature. The membranes were washed 3 
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times in PBS-T then 1.5 mls HRP substrate (Classico) added to each membrane for 3 
minutes and blotted. The membranes were developed on photographic paper.  
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Results 
 
 
Isolation of activated B cells 
 
To investigate the early immunoglobulin response to dengue virus, activated B cells, 
gated as CD19+ CD3/20low/- CD27high CD38high, were isolated from a patient at day – 1 
after defervescence. The lymphocytes were then sorted as single cells (n=48) at sample 
source in Thailand, frozen and transported to the UK. RT-PCR was performed to isolate 
the heavy, lambda and kappa chains from each cell. Nested PCR was then performed on 
the heavy and lambda chains to amplify the product. The kappa chains were sequenced 
before undergoing a cloning PCR.  
 
Production of heavy and light immunoglobulin chains 
 
Nested PCR was then performed on the heavy and lambda chains to amplify the 
product. Positive reactions were identified by loading onto a 1% agarose gel. DNA was 
identified from 35 heavy chains (380bp), 22 lambda chains (405bp) and 20 kappa 
chains (350bp).  
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Fig 15. Immunoglobulin chain nested PCR. 1% agarose gels demonstrating immunoglobulin 
chains isolated and amplified from single sorted antibody secreting cells. 
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The kappa chains were sequenced before undergoing a cloning PCR. The purified PCR 
products of heavy and light chains were digested and expressed in human vectors, Igγ1 
(heavy), Igλ (lambda) and Igκ (kappa), then used to transform competent DH5 E. coli. 
At least 2 colonies of bacteria producing the required DNA were selected for each heavy 
and light chain (heavy 380bp, lambda 405bp, kappa 350bp). DNA produced by the E coli 
was sequenced. 
 
Fig 16. Vector ligation gel. A diagnostic digest was performed to confirm that the 
immunoglobulin chains had been correctly inserted into the appropriate vectors. Digests were 
performed with AgeI and SalI, AgeI and XhoI, and EcoRI and HindIII for the IgH, Igλ and Igκ 
constructs, respectively. Heavy, lambda and kappa chains were identified at 380bp, 405bp 
350bp respectively. 
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Antibody expression by HEK293T cells and concentration measurement 
 
In order to reproduce all potential antibodies (from the combination of heavy and light 
chains) HEK293T cells were co-transfected with all possible permutations of heavy and 
light chains produced from each single B cell, totalling 199 combinations. This 
comprised of 134 IgH-Igλ and 65 IgH-Igκ combinations from 48 single ASC.  
Control transfections were performed with constructs containing DNA from anti-
dengue (3-147 H2K1) (positive control) and anti-flu (2-8CH/λ) (negative control) 
antibodies. The antibody supernatant was harvested after 4 days. A total IgG ELISA of 
the supernatant was then performed assessing the concentration of IgG produced by the 
transfection [Table 8]. In total 88/134 IgH-Igλ and 44/65 IgH-Igκ recombinant IgG 
antibodies were produced from the 199 transfected HEK293T cells. These recombinant 
IgG antibodies were produced from 22 single sorted cells, 13 with a lambda light chain 
and 9 with a kappa light chain.  
Fig 17. Recombinant human IgG concentration ELISA. Supernatant from HEK293T cells was 
incubated on coated ELISA plates. Recombinant human IgG was detected by AP-conjugate anti-
human IgG and measured at 405 – 420 nm. Concentrations were measured by a standard curve 
with purified human IgG: [c] = (0.0259 * Absorbance - 0.0035) * 600. The graph shows the 
conversion of absorbance to concentration.   
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Table 8. Recombinant human IgG concentration ELISA. The table shows the samples chosen 
for further investigation and the concentrations of IgG calculated for each of these samples. 
No.  Sample Concentration 
(g/ml) 
No.  Sample Concentration 
(g/ml) 
1 0623P3_A1_H2K2 6.23 28 Negative control 7.77 
2 0623P3_A1_H2K3 8.17 29 0623P3_A2_H1L1 15.18 
3 0623P3_A3_H1K2 11.61 30 0623P3_A2_H1L2 15.37 
4 0623P3_A3_H1K3 13.56 31 0623P3_A10_H2L2 11.09 
5 0623P3_B2_H2K1 9.09 32 0623P3_A10_H2L3 12.60 
6 0623P3_B2_H2K3 9.73 33 0623P3_B1_H2L1 13.92 
7 0623P3_B3_H1K2 12.13 34 0623P3_B1_H3L1 11.96 
8 0623P3_B3_H1K3 13.64 35 0623P3_B4_H6L1 9.20 
9 0623P3_B7_H1K2 13.18 36 0623P3_B4_H6L2 10.58 
10 0623P3_B7_H1K3 10.50 37 0623P3_B5_H2L7 11.39 
11 0623P3_B8_H4K1 11.26 38 0623P3_B5_H3L7 13.77 
12 0623P3_B8_H4K3 9.06 39 0623P3_B9_H1L1 12.99 
13 0623P3_C2_H2K1 10.77 40 0623P3_B9_H3L1 11.22 
14 0623P3_C2_H3K3 10.33 41 0623P3_B10_H1L1 12.54 
15 0623P3_C8_H1K3 9.60 42 0623P3_B10_H1L3 4.08 
16 0623P3_C8_H2K2 8.62 43 0623P3_C3_H2L6 2.24 
17 0623P3_C9_H2K3 6.62 44 0623P3_C3_H3L6 9.38 
18 0623P3_C9_H3K1 4.85 45 0623P3_C5_H2L2 10.13 
19 0623P3_C11_H1K1 5.14 46 0623P3_C5_H2L3 11.14 
20 0623P3_C11_H1K2 4.60 47 0623P3_A4_H3K3 -1.66 
21 0623P3_D1_H1K3 16.73 48 0623P3_B9_H3K3 -1.77 
21 0623P3_D1_H3K2 18.60 49 0623P3_B12_H2K2 -0.95 
23 0623P3_D3_H1K3 11.14 50 0623P3_C1_H1K2 -1.79 
24 0623P3_D3_H2K3 15.12 51 0623P3_C4_H1K3 -0.65 
25 0623P3_D8_H1K2 12.03 52 0623P3_C10_H1K2 -0.30 
26 0623P3_D8_H2K2 9.69 53 0623P3_B3_H1L1 -1.56 
27 Positive control 6.34    
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A selection from the above 199 samples were then chosen for further investigation. We 
aimed to select 2 samples derived from each positive single B cell. Selections were made 
based on the concentration produced by transfection. Ideal samples had a concentration 
of greater than 10g/ml. However, if concentrations produced did not reach this, a 
sample with the concentration of greater than 4g/ml was used. A selection of one 
clone chosen randomly was made for negative samples. In total 44 positive samples 
were chosen for further assessment. 
 
Identification of dengue specific antibodies  
 
Dot blot of Recombinant antibodies 
A dot blot was performed to assess whether the recombinant IgG produced was against 
dengue or Japanese Encephalitis (JE). The 53 samples above were incubated with UV 
inactivated Dengue 1-4, JE and mock (supernatant from non-infected C6/35 cells, 
negative control). Seven recombinant antibodies showed reactivity to dengue. Three 
antibodies (43%) reacted only to dengue 1. Whereas three (43%) showed cross 
reactivity to all four dengue serotypes, and a further antibody (14%) reacted to all four 
serotypes and additionally to JE. Samples 47 to 53, which were negative on IgG ELISA, 
were also negative by dot blot. 
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Fig 18. Anti-dengue activity and serotype specificity of 53 recombinant antibodies. Dot 
blot of UV treated dengue 1-4, JE and mock, were counter stained with recombinant antibody 
and detected with HRP-conjugated anti-human IgG.  
 
 
 
 
Table 9. Anti-dengue activity and serotype specificity of 53 recombinant antibodies. Table 
showing combined positive results of the dot blot. 
No.  Sample Positive reaction 
9 0623P3_B7_H1K2 DENV 1 
13 0623P3_C2_H2K1 DENV 1 
29 0623P3_A2_H1L1 DENV 1,2,3,4 
33 0623P3_B1_H2L1 DENV 1,2,3,4 
41 0623P3_B10_H1L1 DENV 1,2,3,4 
44 0623P3_C3_H3L6 DENV 1,2,3,4, JE 
46 0623P3_C5_H2L3 DENV 1 
 
 75 
Western blot of dengue specific recombinant antibodies 
 
A western blot was performed in non-reducing conditions to assess the antibodies’ 
epitope. The seven antibodies with reactivity to dengue were assessed against dengue 1. 
Dengue 1 was chosen as the patient had a confirmed dengue 1 illness and therefore it is 
likely that the most avid antibodies would be to dengue 1. Also, all seven recombinant 
antibodies reacted to dengue 1. No recombinant antibodies bound to either the E 
epitope or the prM epitope.  
 
Fig 19. Western blot assessing specific epitopes of recombinant human IgG. Non-reducing 
Western blot of UV-treated DEN1 cell lysates showing reactivity to NS1, prM and E proteins. 
Controls of anti-E (pooled convalescent sample, PCS), anti-NS1, anti-prM (3-147 prM) and 
negative control (X10F, anti-flu) were used.  
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VLP alanine scan library production 
An alanine scan library of dengue VLPs was produced. This library was developed to 
assess the precise residues within the dengue structural proteins that the antibodies 
bind to. Work in the laboratory had already produced a library to dengue 1 with 113 
alanine substitutions. These 113 residues had been chosen according to published work 
on which dengue amino acids were present on the surface of the virus. However, 
crystallography performed on antibodies produced in the laboratory had identified a 
new epitope, the C10 epitope [118].  
 
We produced a library to cover this epitope. There were 67 residues identified on Den 1, 
2 and 4.  
 
 
Fig 20. 3D structure of E protein dimer highlighting the C10 epitope. There are 2 E 
proteins, one in orange and the other in red and yellow. The blue area is the C10 epitope, which 
overlaps the 2 E proteins.  
 
PCRs were performed for each set of primers. A southern blot was performed to confirm VLP 
production.  
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Fig. 21. Southern blot confirming presence of VLP products produced by site direct 
mutagenesis. 
 
The VLPs were then used to transform DH5 E. coli, and the VLPs produced were then 
sent for sequencing to confirm the alanine substitutions. A sample of which is 
demonstrated below showing just the alanine substitutions in the sequence.  VLP 
mutants were produced to 67 residues across 3 dengue serotypes. We were able to 
produce mutants and confirm the correct sequence with alanine substitution to 65 of 
the 67 residues identified as part of the C10 epitope.  
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Fig 22. Representative sample of sequencing results showing presence of alanine 
substitution. After site directed mutagenesis, VLP constructs were sent for sequencing to 
confirm presence of alanine substitution by comparison to wild type VLP prME construct. 
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The VLP products were then used to transfect 293T cells. A dot blot was performed 
from the supernatant of the 293T cells to assess expression. The blot on the left shows 
reactivity to prM and the blot on the right to E. A second run was performed (B) with 
extra mutants identified after the initial run. A third transfection and dot blot (C) was 
performed with samples where expression was either weak or had failed on the initial 
run. Of the 65 mutants with the correct alanine substitution, 6 were not expressed in the 
293T cell supernatant, as demonstrated by dot blot. It is hypothesised that the mutation 
insertion may affect excretion of the particle.  
 
Table 10. Summary of VLP prME constructs and their expression by 293T cells as 
confirmed by dot blot. Expression of VLP construct is represented by +, absent expression by – 
and w meaning weak.  
No. Mutation name Sequence Expression 
by dot blot 
No. Mutation name Sequence Expression 
by dot blot 
1 DV1_Emt_G28A_2 + + 35 DV2_Emt_Q271A_3 + + 
2 DV1_Emt_L46A_3 + + 36 DV2_Emt_S273A_4 + + 
3 DV1_Emt_T68A_1 + + 37 DV2_Emt_L278A_7 + + 
4 DV1_Emt_T69A_3 + + 38 DV2_Emt_V309A_2 + + 
5 DV1_Emt_T70A_1 + + 39 DV2_Emt_D362A_3 + + 
6 DV1_Emt_D71A_2 + + 40 DV2-JE 
K64A_R323A_4 
+ + 
7 DV1_Emt_S72A_2 + + 41 DV4_Emt_G28A_3 + + 
8 DV1_Emt_L82A_6 + + 42 DV4_Emt_I46A_1 + + 
9 DV1_Emt_R99A_6 + + 43 DV4_Emt_N67A_4 + - 
10 DV1_Emt_G102A_3 + + 44 DV4_Emt_I68A_3 + + 
11 DV1_Emt_N103A_3 + + 45 DV4_Emt_T69A_2 + - 
12 DV1_Emt_G104A_9 + + 46 DV4_Emt_T70A_3 + + 
13 DV1_Emt_C105A - - 47 DV4_Emt_A71G_1 + + 
14 DV1_Emt_A245G_3 + + 48 DV4_Emt_T72A_2 + + 
15 DV1_Emt_K246A_3 + + 49 DV4_Emt_L82A_1 + + 
16 DV1_Emt_Q271A_6 + + 50 DV4_Emt_K83A_1 + + 
17 DV2_Emt_G28A_3 + + 51 DV4_Emt_R99A_5 + + 
18 DV2_Emt_I46A_2 + + 52 DV4_Emt_W101A_4 + + 
19 DV2_Emt_N67A_2 + + 53 DV4_Emt_G102A_2 + + 
20 DV2_Emt_T68A_2 + + 54 DV4_Emt_N103A_2 + - 
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21 DV2_Emt_T69A_2 + + 55 DV4_Emt_G104A_3 + + 
22 DV2_Emt_T70A_6 + + 56 DV4_Emt_C105A_12 + + 
23 DV2_Emt_E71A_11 - W 57 DV4_Emt_G106A_3 + + 
24 DV2_Emt_S72A_1 + + 58 DV4_Emt_A245G_2 + + 
25 DV2_Emt_L82A + - 59 DV4_Emt_K246A_1 + + 
26 DV2_Emt_N83A_1 + + 60 DV4_Emt_D271A_3 + + 
27 DV2_Emt_R99A_2 + + 61 DV4_Emt_G273A_1 + + 
28 DV2_Emt_G102A_4 + + 62 DV4_Emt_M278A_1 + + 
29 DV2_Emt_N103A_4 + - 63 DV4_Emt_D309A_1 + + 
30 DV2_Emt_G104A_1 + + 64 DV4_Emt_K310A_4 + + 
31 DV2_Emt_C105A_3 + - 65 DV4_Emt_K323A_1 + + 
32 DV2_Emt_G106A_4 + + 66 DV4_Emt_K323G_1 + + 
33 DV2_Emt_A245G_6 + + 67 DV4_Emt_N362A_2 + + 
34 DV2_Emt_K246A_2 + +     
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Fig. 23 Expression of VLP prME constructs assessed by dot blot. Membranes were dotted 
with the VLP constructs and counter stained with anti-prM (1H10) and anti-E (4G2) antibodies. 
Each dot represents an individual VLP mutant (list in appendix 1). Fig A represents the initial 
sample run. Figure B represent further samples that were assessed in addition to run A. Figure C 
represents repeat sample runs for the samples that had either weak or absent expression in run 
A.  
 
In summary, 65 prME VLP mutants were successfully produced with alanine 
substitutions for wild type amino acids. Of these 65, 59 samples were expressed by 
293T cells. Thus a library was created against which recombinant antibodies can be 
tested to assess key binding residues within the C10 epitope 
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Discussion 
 
 
Primary dengue infection has rarely been studied. In this preliminary study, I 
investigated the acute response to primary dengue haemorrhagic fever as a result of 
dengue 1 infection.  
 
Monoclonal antibodies have been used to study the complex immune response to 
dengue virus. Traditionally, monoclonal antibodies have been raised in mice. However, 
recent advances in in vitro techniques have allowed the study of monoclonal antibodies 
in response to acute and convalescent infection.  
 
The advances in in vitro techniques have meant that relatively large numbers of 
monoclonal antibodies have been able to be generated in humans. Thus allowing the 
study of human responses to dengue infection. One technique has been the EBV 
immortalisation of memory B cells and the other uses a sensitive single cell 
immunoglobulin PCR. The latter of which was used in this study. The disadvantages of 
EBV immortalisation are the inefficiency of transformation (1-3%) that is highly 
dependent on cell stage, and thus cannot be used to assess immunoglobulin usage 
within a cell population. Also, as only memory B cells can be assessed, the acute 
response to infection cannot be studied.  The technique used in this study was chosen 
for a number of reasons. Firstly, it uses activated plasmablasts during an active 
infection. This means that many of the cells are antigen specific and reflective of the 
natural immune response. This method is also highly efficient and allows relatively easy 
production of large numbers of unbiased monoclonal antibodies.  
 
Work using these new techniques has shown us that the human response to infection is 
quite different from that in the mouse model. In mice the antibody response is 
dominated by neutralising antibodies to the E protein, domain III (EDIII) [113] [114] 
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[115] [116]. In humans, EDIII antibodies are much less frequent. Through studies using 
immunodepletion, it has been shown that these antibodies have little effect on 
neutralising capacity. In fact, a large proportion of antibodies produced in humans are 
against prM and the fusion loop (a highly conserved short section of domain II) [120] 
[148] [149]. 
 
Acute phase antibody response to dengue 
 
There have been three studies to date investigating the acute antibody response to 
dengue infection. Two of the studies are based on the same patient data. In the studies 
by Pipattanaboon and Setthapramote, four patients with acute infection (1 week after 
onset of fever) and five patients with convalescent infection were studied.  From the 
four acute patients, 111 monoclonal antibodies were generated. Serological reactivity 
was assessed by immunofluorescence. This revealed that 90% of clones derived from 
acute phase patients were cross reactive to all four serotypes, whereas only 46.7% of 
clones from convalescent patients was cross reactive to all four serotypes. Epitope 
binding was assessed by immunofluorescence. The majority of antibodies were directed 
against E protein (89%), with only small numbers directed against prM (7%), NS1 (4%) 
and none to C protein. However, 60% of the antibodies were generated from one 
patient, so caution should be applied when assessing these figures. The patient that 
contributed most antibodies had an antibody response to all three proteins 
investigated, with 84% being against E, 12% being against prM and 4% being against 
NS1. Of the mAbs from the convalescent patients, two were reactive with E (17%), two 
with prM (17%), 8 with NS1 (66%) and none with C [150, 151].   
 
 
In the second study, this by Sasaki, three patients with acute dengue (day 5-8 after onset 
of fever), one of whom had dengue haemorrhagic fever, were investigated. 17 
monoclonal antibodies that were strongly neutralizing to all four serotypes were 
selected for investigation; therefore breadth of antibody response cannot be assessed 
from this study. All of the mAbs reacted to E protein. It was found by western blot, that 
13 of the 17 mAbs had an epitope between residues 53 and 132, the epitope lying across 
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DI and DII of the E protein. The remaining 4 mAbs did not react with either truncated 
forms or the full length form, indicated that their binding is conformation dependent 
[126].  
 
 
Convalescent sera 
There have been three studies investigating the breadth of antibody response to 
dengue in convalescence. In the study by de Alwis, 1 patient with convalescent primary 
dengue was assessed for breadth of reponse. They found that 93% (13/14) of 
antibodies cross reacted with all four dengue serotypes. The majority of the clones 
mapped to prM (71%), with 7% mapping to E protein and a further 21% that were not 
reactive on western blot [148]. A second study isolated 70 mAbs from 5 donors, 3 with 
convalescent primary infection and 2 with secondary. Of the 70 mAbs, 47 (67%) were 
reactive to E protein. Of the patients with primary disease, mAb reactivity was as 
follows: DI/II 39%, DIII 20%, prM 12%, NS1 17%, NS3 10%, C 2%. Patients with 
secondary infection had the following mAb responses: DI/II 77%, DIII 17%, prM 3%, 
not classified 3%. In the third paper 40 mAbs were isolated with 48% being direct 
against E protein and 8% being directed against NS1 [143]. However, reactivity to 
other epitopes was not tested [152].  
 
These studies demonstrate that the breadth of antibody reponse in both acute illness 
and convalescence varies markedly between individuals with some having a dominant 
reponse to E and other recognising a wide variety of epitopes. 
 
 
Isolation of anti-dengue antibodies  
 
In this study, I isolated recombinant antibodies from an acute case of dengue 
haemorrhagic fever. A dot blot was performed to assess whether the antibodies bound 
to dengue 1, or indeed any other serotype of dengue or Japanese encephalitis virus. I 
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found that despite the very early time point in infection (day -1 before defervescence), 
the patient was already producing antibodies against dengue.  Of the 53 antibodies 
assessed, 7 (13%) showed reactivity to dengue.  Three of the 7 clones (43%) reacted to 
dengue 1 only, 3 (43%) were cross reactive to all four dengue serotypes and a further 
clone (14%) cross reacted not only with all four dengue serotypes, but also Japanese 
encephalitis virus. It has been well known that in early convalescence following dengue 
infection, patients develop cross reactive antibodies to all four serotypes and that this 
acts as protection from a further dengue infection for up to 18 months. However, it is 
interesting to see that these antibodies are being produced so early in infection. This 
concurs with the data from Setthapramote showing a high degree of cross reactivity 
among antibodies produced in the acute phase. However from the results produced by 
this study, this is not the full story. It appears antibody responses are not all cross-
reactive, but that there is a specific anti-dengue 1 immune response very early in 
infection.  
 
 
Assessment of epitope binding of antibodies 
A western blot was performed to assess whether the antibodies bound to either prM or 
E protein. Interestingly, we found that no antibodies bound to either structural protein. 
This suggests that either the antibodies produced were against another dengue protein, 
or else they bind across a complex epitope. Although the western blot was performed in 
non-reducing conditions, the proteins may have lost some of their natural conformation 
and therefore the results may be misleading. Further assessment of epitope binding will 
need to be performed, by repeating the western blot and assessing binding using an 
alanine scan. To this end a VLP library was generated.  
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prME VLP library and alanine scan 
 
In order to identify the precise location of mAb binding within either the prM or the E 
proteins a VLP library was created. Each amino acid from the exposed surfaces of the E 
and prM proteins is substituted within an alanine amino acid. The mAbs are then tested 
by capture ELISA against these mutated proteins and a key residue for binding is found 
when binding to the protein is lost. Alanine is chosen for its small, chemically inert 
methyl group and its ability to mimic the secondary structure of many other amino 
acids. There are limitations to this technique. The prME VLPs are not homogenous in 
structure and most are smaller than the dengue virion, containing only 30E dimers, 
displaying a different arrangement to the 90E dimer virion. The difference in packing of 
structural proteins may therefore alter the ability of the alanine scan to detect 
quaternary binding.  The use of alanine as a substitute may also be too conservative to 
assess epitope binding, because either the electrostatic charge is too weak or else the 
epitope binding may rely on binding to the main amino acid chain rather than the side 
chain. However, it had been used successfully to identify many epitopes for mAb 
binding [118].  
 
A prME VLP library had already been generated within the laboratory too much of the 
prM and E proteins. However, a new epitope, the C10 epitope had recently been 
identified in the laboratory, and as such the library required extending. 67 residues 
were identified as part of the C10 epitope. Of these we managed to create 65 stable 
mutants, and express 59 of them through 293T cells. Transfection may have failed in 6 
cases either because of a failure in transfection or because the mutations introduced to 
the VLPs affected their excretion from the cells. Therefore the transfection plates of the 
failed transfections were stored for later staining to determine whether the VLPs 
remained in an intracellular compartment. Unfortunately because of the time taken to 
generate the VLP library, we were unable to test our clones against the library. This 
work will be performed in the laboratory at a later date.  
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For the antibodies that appear particularly interesting, X-ray crystallography could be 
additionally used to assess epitope binding further. Further assessment of the 
antibodies generated would also include functional assessment of the mAbs. This would 
involve performing neutralisation and antibody-enhancement assays. Thus describing 
not only what early antibodies to primary infection bind to, but also whether they are 
helpful at controlling infection or are detrimental through virus enhancement.  
 
Summary 
 
In this study, monoclonal IgG antibodies were isolated from a patient with primary 
severe dengue whilst still in the febrile phase of the illness. Of the 53 monoclonal 
antibodies produced, seven were reactive against dengue. Of these, 43% were reactive 
to the infecting serotype only, whilst another 43% were reactive to all four dengue 
serotypes. This demonstrates that an IgG response is produced very early even in 
primary infection and that it is not only serotype specific, but some of the response is 
cross reactive. Western blot of the antibodies did not reveal the epitopes to which the 
antibodies react.  
 
Further proposed work 
 
Unfortunately, due to time pressure I was not able to complete all my investigations. As 
a result, I would like to propose future work that may be useful in studying the area 
further. 
 
Firstly, I would like to investigate epitope binding further. In this, I would like to repeat 
the Western Blot and extend the epitopes tested against to include C, NS1 and perhaps 
other non-structural proteins. I would also like to test the antibodies produced against 
the VLP library I have generated. Hopefully, through these experiments, I would be able 
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to elucidate which epitopes the antibodies react against. The results would allow us to 
understand whether in severe primary disease, antibodies are contributing to 
pathogenesis, as prM antibodies are thought to enhance infection by rendering non-
infectious particles infectious.  
 
The second set of experiments I would like to undertake would be to assess the 
functionality of the antibodies. By performing neutralisation and enhancement assays, I 
could assess the effect of the antibodies on infection. Again help assess the contribution 
of antibodies to pathogenesis in severe primary disease.  
 
Thirdly, I would like to return to the primary samples and assess IgM production and its 
contribution to anti-dengue antibodies and pathogenesis. I feel that this would be very 
instructive in understanding the relative contribution of antibodies to disease. 
 
Fourthly, it would be very interesting to compare the results obtained from this patient 
with severe primary disease to that of a patient with primary dengue but without severe 
disease and ideally an asymptomatic primary patient as well. This in particular would 
give an insight into the role of antibodies in the development of clinical disease.  
 
Studying patients with primary disease gives an interesting insight into the body’s 
response to dengue and why some patients are incredibly ill, whilst most are 
asymptomatic. This is a fascinating area of research that should prove fruitful not only 
improving knowledge, but also in the design of safe and effective vaccination.  
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